Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all
“Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France.” The Breast.
@article{article67572,
title = {Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002493?dgcid=rss_sd_all}
}